Return to Listing

4 result(s) for sutent

PI Name Protocol # Title
Stephen Spurgeon IRB00007195 A Phase II Proof of Concept Trial to Study Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using a Comprehensive in Vitro Kinase Inhibitor Panel to Select Individualized Targeted Therapies
Stephen Spurgeon IRB00011766 A Phase Ib Feasibility Study of Personalized Kinase Inhibitor Therapy Combined with Induction Chemotherapy in Acute Myeloid Leukemia in Patients who Exhibit in vitro Kinase Inhibitor Sensitivity
Christopher Ryan STUDY00016085 [NCI CIRB] A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Christopher Ryan STUDY00016300 A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426)
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080